MaxCyte Preliminary Q4 Core Revenue Improves

January 13, 2025 — 03:38 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - MaxCyte, Inc. (MXCT), a cell engineering firm, said on Monday that it expects to post its fourth-quarter core revenue in the range of $8.3 million to $8.5 million, compared with $7.2 million, registered for the same period last year. For the full year, according to the company's preliminary estimates, core revenue is expected to be in the range of $32.2 million to $32.4 million, higher than $29.8 million of the prior year.

Maher Masoud, CEO of MaxCyte, said: "The operating environment in the cell therapy industry is improving as we move into 2025, and we remain confident in the opportunity that exists for MaxCyte in the years ahead. In 2024, we increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations."

The company is expected to release its full-year SPL program-related revenue and total revenue in March.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

MaxCyte Preliminary Q4 Core Revenue Improves

Tags

Latest Articles